Allegra contains fexofenadine, an antihistamine for systemic use indicated in the management of allergic conditions, including hay fever and associated febrile symptoms. The brand sits within the broader antiallergic category and is one of the more recognisable fexofenadine-containing products on the international market.
Fexofenadine is prescribed for the relief of symptoms driven by histamine release — most commonly seasonal and perennial allergic rhinitis, of which hay fever is the most familiar form. The structured indication list further down this page details the registered uses recognised across each of the markets where Allegra is sold, which can vary in scope from one regulator to another.
Allegra carries marketing authorisation in 24 countries, with a footprint that mixes Latin American markets, Central and Eastern European countries, and parts of Asia. Representative examples include Japan, Brazil, India, Hungary, and Colombia. Travellers and expatriates moving between these regions will often encounter the same brand on pharmacy shelves, although packaging, labelling language, and prescription status can shift considerably from one jurisdiction to another — in some markets fexofenadine products are over the counter, in others they remain behind the counter.
Other antihistamines for systemic use are sold worldwide under different molecules and brand names, and fexofenadine itself circulates under several generic labels in markets where the original patent has expired. A local pharmacist is well placed to identify the appropriate regional product, whether that means the same brand, a fexofenadine generic, or a different antihistamine. Anyone considering Allegra, currently taking it, or trying to match it to a local product abroad should make that decision together with a qualified healthcare provider.
Allegra is prescribed for the management of allergic conditions, including hay fever (seasonal allergic rhinitis) and associated febrile symptoms. As an antihistamine for systemic use, it falls within the broader antiallergic category that addresses the symptoms triggered by histamine release. The structured indication block below this introduction lists the specific registered uses recognised in each of the markets where Allegra is sold.
Allegra contains fexofenadine, classified as an antihistamine for systemic use within the broader antiallergic category. Fexofenadine is the same molecule whether sold under the Allegra brand or as a generic — internationally, the same active ingredient circulates under multiple commercial names, particularly in markets where several manufacturers produce fexofenadine-containing products in parallel.
Allegra is registered in 24 countries, with a footprint that spans Latin America, Central and Eastern Europe, and parts of Asia. Representative markets include Japan, Brazil, India, Hungary, Colombia, and Austria. If your country is not on this list, a local pharmacist can usually confirm whether fexofenadine is available in that market under a different brand name or as a generic.
Fexofenadine is sold under several brand names worldwide, particularly in markets where the original patent has expired and generic manufacturers have entered. Other medications within the systemic antihistamine class also exist under different molecules, although they are not directly interchangeable without guidance. To identify a local fexofenadine-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Prescription status for fexofenadine-containing products varies between countries — in some markets Allegra is available over the counter, while in others it requires a prescription. Travellers and expatriates should not assume that the rules they know from home apply abroad. A healthcare provider familiar with the patient's circumstances, and a pharmacist familiar with the local regulatory framework, are the right people to consult before starting or continuing therapy.
